original articlesgastrointestinal tumorsContinuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
gastrointestinal tumors
Under an Elsevier user license
open archive
metastatic colorectal cancer
bevacizumab
second-line
beyond progression
Cited by (0)
- †
Members are listed in supplementary Appendix, available at Annals of Oncology online.
Copyright © 2015 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.